article

1. CYP1B1-RMDN2 Alzheimer's disease endophenotype locus identified for cerebral tau PET..  Nature communications.  15:-. 2024
2. Neuropsychiatric symptom burden in early-onset and late-onset Alzheimer's disease as a function of age..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  20:5481-5491. 2024
3. Biomarker-based staging of Alzheimer disease: rationale and clinical applications..  Nature reviews. Neurology.  20:232-244. 2024
4. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis..  The Lancet. Neurology.  23:168-177. 2024
5. Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer's disease..  Cell reports.  43:-. 2024
6. TAF15 amyloid filaments in frontotemporal lobar degeneration..  Nature.  625:345-351. 2023
7. BrainAGE Estimation: Influence of Field Strength, Voxel Size, Race, and Ethnicity..  medRxiv : the preprint server for health sciences.  2023
8. Associations Between Social Network Characteristics and Brain Structure Among Older Adults..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  20:1406-1420. 2023
9. Edge time series components of functional connectivity and cognitive function in Alzheimer's disease..  Brain imaging and behavior.  18:243-255. 2023
10. Edge Time Series Components of Functional Connectivity and Cognitive Function in Alzheimer's Disease..  medRxiv : the preprint server for health sciences.  2023
11. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics..  Brain : a journal of neurology.  146:4414-4424. 2023
12. The Sporadic Early-onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cohort..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S74-S88. 2023
13. Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S64-S73. 2023
14. Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS)..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S98-S114. 2023
15. The relationship between learning slopes and Alzheimer's Disease biomarkers in cognitively unimpaired participants with and without subjective memory concerns..  Journal of clinical and experimental neuropsychology.  45:1-17. 2023
16. Influence of amyloid and diagnostic syndrome on non-traditional memory scores in early-onset Alzheimer's disease..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S29-S41. 2023
17. Spatial transcriptomic patterns underlying regional vulnerability to amyloid-β and tau pathologies and their relationships to cognitive dysfunction in Alzheimer's disease..  medRxiv : the preprint server for health sciences.  2023
18. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial..  JAMA.  330:512-527. 2023
19. Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S49-S63. 2023
20. Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S115-S125. 2023
21. White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS)..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S89-S97. 2023
22. GRB14.  medRxiv : the preprint server for health sciences.  2023
23. A simulative deep learning model of SNP interactions on chromosome 19 for predicting Alzheimer's disease risk and rates of disease progression..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19:5690-5699. 2023
24. Developments in understanding early onset Alzheimer's disease..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S126-S131. 2023
25. Amyloid and tau pathology are associated with cerebral blood flow in a mixed sample of nondemented older adults with and without vascular risk factors for Alzheimer's disease..  Neurobiology of aging.  103-113. 2023
26. Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S42-S48. 2023
27. Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S8-S18. 2023
28. Accelerating diversity in Alzheimer's disease research by partnering with a community advisory board..  Alzheimer's & dementia (New York, N. Y.).  9:-. 2023
29. Learning slopes in early-onset Alzheimer's disease..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S19-S28. 2023
30. Social enrichment on the job: Complex work with people improves episodic memory, promotes brain reserve, and reduces the risk of dementia..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19:2655-2665. 2023
31. CYP1B1-RMDN2.  medRxiv : the preprint server for health sciences.  2023
32. APOE ε4 is associated with earlier symptom onset in LOAD but later symptom onset in EOAD..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19:2212-2217. 2023
33. Neuroimaging in Dementia..  Continuum (Minneapolis, Minn.).  29:219-254. 2023
34. Association of Brain Volume and Retinal Thickness in the Early Stages of Alzheimer's Disease..  Journal of Alzheimer's disease : JAD.  91:743-752. 2023
35. Criterion Validation of Tau PET Staging Schemes in Relation to Cognitive Outcomes..  Journal of Alzheimer's disease : JAD.  96:197-214. 2023
36. Lecanemab: Appropriate Use Recommendations..  The journal of prevention of Alzheimer's disease.  10:362-377. 2023
37. Altered cerebral blood flow in older adults with Alzheimer's disease: a systematic review..  Brain imaging and behavior.  17:223-256. 2022
38. APOE ε4 carrier status and sex differentiate rates of cognitive decline in early- and late-onset Alzheimer's disease..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19:1983-1993. 2022
39. Sensitivity of memory subtests and learning slopes from the ADAS-Cog to distinguish along the continuum of the NIA-AA Research Framework for Alzheimer's Disease..  Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition.  30:1-19. 2022
40. Designing the next-generation clinical care pathway for Alzheimer's disease..  Nature aging.  2:692-703. 2022
41. Social Networks and Cognitive Reserve: Network Structure Moderates the Association Between Amygdalar Volume and Cognitive Outcomes..  The journals of gerontology. Series B, Psychological sciences and social sciences.  77:1490-1500. 2022
42. Validation of and Demographically Adjusted Normative Data for the Learning Ratio Derived from the RAVLT in Robustly Intact Older Adults..  Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.  37:981-993. 2022
43. Social Networks and Cognitive Function: An Evaluation of Social Bridging and Bonding Mechanisms..  The Gerontologist.  62:865-875. 2022
44. Assessing and validating reliable change across ADNI protocols..  Journal of clinical and experimental neuropsychology.  44:85-102. 2022
45. Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's disease..  Brain : a journal of neurology.  145:2149-2160. 2022
46. Atypical Alzheimer Disease Variants..  Continuum (Minneapolis, Minn.).  28:676-701. 2022
47. Do subjective or objective cognitive measures better predict social network type among older adults?.  Biodemography and social biology.  67:1-14. 2022
48. Virtual reality cognitive intervention for heart failure: CORE study protocol..  Alzheimer's & dementia (New York, N. Y.).  8:-. 2022
49. Examining the role of repeated test exposure over 12 months across ADNI protocols..  Alzheimer's & dementia (Amsterdam, Netherlands).  14:-. 2022
50. Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  18:1957-1968. 2022
51. Characterization of gene expression patterns in mild cognitive impairment using a transcriptomics approach and neuroimaging endophenotypes..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  18:2493-2508. 2022
52. Cognitively stimulating environments and cognitive reserve: the case of personal social networks..  Neurobiology of aging.  197-203. 2022
53. Associations between Cortical Thickness and Metamemory in Alzheimer's Disease..  Brain imaging and behavior.  16:1495-1503. 2022
54. Aducanumab: Appropriate Use Recommendations Update..  The journal of prevention of Alzheimer's disease.  9:221-230. 2022
55. Measuring Subjective Cognitive Decline in Older Adults: Harmonization Between the Cognitive Change Index and the Measurement of Everyday Cognition Instruments..  Journal of Alzheimer's disease : JAD.  87:761-769. 2022
56. Why the cognitive "fountain of youth" may be upstream: Pathways to dementia risk and resilience through social connectedness..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  18:934-941. 2021
57. Head injury is associated with tau deposition on PET in MCI and AD patients..  Alzheimer's & dementia (Amsterdam, Netherlands).  13:-. 2021
58. Predicting the Emergence of Major Neurocognitive Disorder Within Three Months After a Stroke..  Frontiers in aging neuroscience.  -. 2021
59. Treatment Challenges and the Hope of Emerging Therapies in Early-Stage Alzheimer Disease..  The Journal of clinical psychiatry.  82. 2021
60. Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer's disease..  Alzheimer's research & therapy.  13:-. 2021
61. Temporal stability of the ventral attention network and general cognition along the Alzheimer's disease spectrum..  NeuroImage. Clinical.  -. 2021
62. The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  17:2043-2055. 2021
63. Talking With Patients and Care Partners About Treatment Goals and Challenges in Early-Stage Alzheimer Disease..  The Journal of clinical psychiatry.  82. 2021
64. Optimizing differential identifiability improves connectome predictive modeling of cognitive deficits from functional connectivity in Alzheimer's disease..  Human brain mapping.  42:3500-3516. 2021
65. Early-Stage Alzheimer Primer: Pathophysiology, Diagnosis, and Assessment..  The Journal of clinical psychiatry.  82. 2021
66. Donanemab in Early Alzheimer's Disease..  The New England journal of medicine.  384:1691-1704. 2021
67. New insights into atypical Alzheimer's disease in the era of biomarkers..  The Lancet. Neurology.  20:222-234. 2021
68. Aducanumab: Appropriate Use Recommendations..  The journal of prevention of Alzheimer's disease.  8:398-410. 2021
69. Tau-related white-matter alterations along spatially selective pathways..  NeuroImage.  -. 2020
70. Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  16:1213-1223. 2020
71. Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis..  Alzheimer's research & therapy.  12:-. 2020
72. Testing influences of APOE and BDNF genes and heart failure on cognitive function..  Heart & lung : the journal of critical care.  50:51-58. 2020
73. Neurodegenerative Patterns of Cognitive Clusters of Early-Onset Alzheimer's Disease Subjects: Evidence for Disease Heterogeneity..  Dementia and geriatric cognitive disorders.  48:131-142. 2020
74. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study..  BMJ open.  9:-. 2019
75. Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease..  NPJ Parkinson's disease.  -. 2019
76. Epigenome-wide meta-analysis of blood DNA methylation and its association with subcortical volumes: findings from the ENIGMA Epigenetics Working Group..  Molecular psychiatry.  26:3884-3895. 2019
77. Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition..  Alzheimer's & dementia (Amsterdam, Netherlands).  510-519. 2019
78. The Functional Ability of MCI and Alzheimer's Patients Predicts Caregiver Burden..  GeroPsych.  32:31-39. 2019
79. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing..  Nature genetics.  51:414-430. 2019
80. Volumetric comparison of hippocampal subfields extracted from 4-minute accelerated vs. 8-minute high-resolution T2-weighted 3T MRI scans..  Brain imaging and behavior.  12:1583-1595. 2018
81. Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis..  JAMA neurology.  75:328-341. 2018
82. Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging..  Alzheimer disease and associated disorders.  32:35-42. 2018
83. Associations between hippocampal morphometry and neuropathologic markers of Alzheimer's disease using 7 T MRI..  NeuroImage. Clinical.  56-61. 2017
84. Building a Surface Atlas of Hippocampal Subfields From High Resolution T2-weighted MRI Scans Using Landmark-free Surface Registration..  The ... Midwest Symposium on Circuits and Systems conference proceedings : MWSCAS. Midwest Symposium on Circuits and Systems.  2017
85. Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials..  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.  14:62-68. 2017
86. The effect of the top 20 Alzheimer disease risk genes on gray-matter density and FDG PET brain metabolism..  Alzheimer's & dementia (Amsterdam, Netherlands).  53-66. 2016
87. Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care..  Alzheimer's & dementia (Amsterdam, Netherlands).  15-22. 2016
88. A comparison of theoretical and statistically derived indices for predicting cognitive decline..  Alzheimer's & dementia (Amsterdam, Netherlands).  171-181. 2016
89. Novel verbal fluency scores and structural brain imaging for prediction of cognitive outcome in mild cognitive impairment..  Alzheimer's & dementia (Amsterdam, Netherlands).  113-22. 2016
90. Plasma BDNF levels associate with Pittsburgh compound B binding in the brain..  Alzheimer's & dementia (Amsterdam, Netherlands).  1:187-193. 2015
91. Clinical, FDG and amyloid PET imaging in posterior cortical atrophy..  Journal of neurology.  262:1483-92. 2015
92. Use of the MoCA in Detecting Early Alzheimer's Disease in a Spanish-Speaking Population with Varied Levels of Education..  Dementia and geriatric cognitive disorders extra.  5:85-95. 2015
93. Manual segmentation qualification platform for the EADC-ADNI harmonized protocol for hippocampal segmentation project..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  11:161-74. 2015
94. Rarity of the Alzheimer disease-protective APP A673T variant in the United States..  JAMA neurology.  72:209-16. 2015
95. Comparing 3T and 1.5T MRI for mapping hippocampal atrophy in the Alzheimer's Disease Neuroimaging Initiative..  AJNR. American journal of neuroradiology.  36:653-60. 2015
96. Relationship between hippocampal atrophy and neuropathology markers: a 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  11:139-50. 2015
97. Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures..  Neurology.  84:729-37. 2015
98. Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort..  Dementia and geriatric cognitive disorders.  39:154-66. 2014
99. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study..  JAMA neurology.  71:1394-404. 2014
100. The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  11:111-25. 2014
101. Harmonized benchmark labels of the hippocampus on magnetic resonance: the EADC-ADNI project..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  11:151-60.e5. 2014
102. Delphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  11:126-38. 2014
103. Age effects on cortical thickness in cognitively normal elderly individuals..  Dementia and geriatric cognitive disorders extra.  4:221-7. 2014
104. The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data..  Brain imaging and behavior.  8:153-82. 2014
105. The "Alzheimer's type" profile of semantic clustering in amnestic mild cognitive impairment..  Journal of the International Neuropsychological Society : JINS.  20:402-12. 2014
106. Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease..  Dementia and geriatric cognitive disorders.  37:315-26. 2014
107. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease..  NeuroImage. Clinical.  461-72. 2014
108. Establishing magnetic resonance images orientation for the EADC-ADNI manual hippocampal segmentation protocol..  Journal of neuroimaging : official journal of the American Society of Neuroimaging.  24:509-14. 2013
109. Reliability of two-dimensional and three-dimensional pseudo-continuous arterial spin labeling perfusion MRI in elderly populations: comparison with 15O-water positron emission tomography..  Journal of magnetic resonance imaging : JMRI.  39:931-9. 2013
110. Alzheimer disease: 'generation next' in Alzheimer disease genetic studies..  Nature reviews. Neurology.  9:422-3. 2013
111. Multilocus genetic profiling to empower drug trials and predict brain atrophy..  NeuroImage. Clinical.  827-35. 2013
112. Similar verbal fluency patterns in amnestic mild cognitive impairment and Alzheimer's disease..  Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.  28:400-10. 2013
113. Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  28:302-10. 2013
114. Cortical thickness and semantic fluency in Alzheimer's disease and mild cognitive impairment..  American journal of Alzheimer's disease (Columbia, Mo.).  1:81-92. 2013
115. Mapping cortical atrophy in Parkinson's disease patients with dementia..  Journal of Parkinson's disease.  3:69-76. 2013
116. Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study..  Alzheimer disease and associated disorders.  27:174-81. 2013
117. Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson's disease..  Journal of neurology, neurosurgery, and psychiatry.  84:23-8. 2012
118. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study..  Alzheimer's research & therapy.  4:-. 2012
119. Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer's disease mutations..  Journal of neurology, neurosurgery, and psychiatry.  84:154-62. 2012
120. Comparing hippocampal atrophy in Alzheimer's dementia and dementia with lewy bodies..  Dementia and geriatric cognitive disorders.  34:44-50. 2012
121. Agitation and psychosis associated with dementia with lewy bodies exacerbated by modafinil use..  American journal of Alzheimer's disease and other dementias.  27:468-73. 2012
122. Novel late-onset Alzheimer disease loci variants associate with brain gene expression..  Neurology.  79:221-8. 2012
123. Identification of common variants associated with human hippocampal and intracranial volumes..  Nature genetics.  44:552-61. 2012
124. Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative..  Neurobiology of aging.  34:62-72. 2012
125. Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer Disease..  Alzheimer disease and associated disorders.  26:17-27. 2012
126. Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease..  Dementia and geriatric cognitive disorders.  32:118-25. 2011
127. Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment..  Neurobiology of aging.  33:2113-24. 2011
128. Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation..  Neuroscience letters.  487:287-92. 2010
129. Effects of ApoE4 and maternal history of dementia on hippocampal atrophy..  Neurobiology of aging.  33:856-66. 2010
130. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects..  Neurobiology of aging.  31:1284-303. 2010
131. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI..  Human brain mapping.  31:786-97. 2010
132. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia..  Movement disorders : official journal of the Movement Disorder Society.  25:687-95. 2010
133. Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects..  NeuroImage.  51:488-99. 2010
134. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls..  Human brain mapping.  30:2766-88. 2009
135. Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly..  Molecular imaging and biology.  12:218-24. 2009
136. Comparison of AdaBoost and support vector machines for detecting Alzheimer's disease through automated hippocampal segmentation..  IEEE transactions on medical imaging.  29:30-43. 2009
137. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls..  NeuroImage.  45:S3-15. 2008
138. Use of magnetic resonance imaging to identify mild cognitive impairment: who should be imaged?.  CNS spectrums.  13:18-20. 2008
139. Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal..  Neurobiology of aging.  31:1077-88. 2008
140. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls..  NeuroImage.  43:59-68. 2008
141. Automatic subcortical segmentation using a contextual model..  Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention.  11:194-201. 2008
142. Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment..  Neuropsychologia.  46:1597-612. 2007
143. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature..  Dementia and geriatric cognitive disorders.  25:115-26. 2007
144. Computational anatomical methods as applied to ageing and dementia..  The British journal of radiology.  S78-91. 2007
145. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease..  Archives of neurology.  64:1489-95. 2007
146. Brain mapping as a tool to study neurodegeneration..  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.  4:387-400. 2007
147. Structural correlates of apathy in Alzheimer's disease..  Dementia and geriatric cognitive disorders.  24:91-7. 2007
148. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations..  Brain : a journal of neurology.  130:1767-76. 2007
149. 3D mapping of language networks in clinical and pre-clinical Alzheimer's disease..  Brain and language.  104:33-41. 2007
150. 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease..  Brain : a journal of neurology.  129:2867-73. 2006
151. Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there?.  Expert review of neurotherapeutics.  6:1293-306. 2006
152. Multiple system atrophy presenting with language impairment..  Neurology.  67:726-7. 2006
153. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps..  Archives of neurology.  63:693-9. 2006
154. 3D mapping of mini-mental state examination performance in clinical and preclinical Alzheimer disease..  Alzheimer disease and associated disorders.  20:224-31. 2006
155. Disseminated Pseudallescheria boydii infection successfully treated with voriconazole..  Journal of neurology, neurosurgery, and psychiatry.  76:1741-2. 2005
156. Deep white matter pathologic features in watershed regions: a novel pattern of central nervous system involvement in MELAS..  Archives of neurology.  62:1154-6. 2005